Targeted therapy of RET fusion-positive non-small cell lung cancer

被引：14

作者：

Shen, Zixiong ^{[1
]}

Qiu, Binxu ^{[2
]}

Li, Lin ^{[1
]}

Yang, Bo ^{[1
]}

Li, Guanghu ^{[1
]}

机构：

[1] First Hosp Jilin Univ, Dept Thorac Surg, Changchun, Peoples R China

[2] First Hosp Jilin Univ, Dept Gastrointestinal Surg, Changchun, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

non-small cell lung cancer (NSCLC); RET gene; RET fusion; targeted therapy; cancer biology; ACQUIRED-RESISTANCE MECHANISM; SOLVENT-FRONT; OPEN-LABEL; ANTITUMOR-ACTIVITY; TRANSFORMING GENE; ALK; ALECTINIB; REARRANGEMENTS; SELPERCATINIB; CABOZANTINIB;

D O I：

10.3389/fonc.2022.1033484

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with considerable efficacy. The RET proto-oncogene is located on the long arm of chromosome 10 with a length of 60,000 bp, and the expression of RET gene affects cell survival, proliferation, growth and differentiation. This review will describe the basic characteristics and common fusion methods of RET genes; analyze the advantages and disadvantages of different RET fusion detection methods; summarize and discuss the recent application of non-selective and selective RET fusion-positive inhibitors, such as Vandetanib, Selpercatinib, Pralsetinib and Alectinib; discuss the mechanism and coping strategies of resistance to RET fusion-positive inhibitors.

引用

页数：13

共 114 条

[1] Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC) [J].

Adhikary, Ritu ;

Khandelwal, Ravina ;

Hussain, Tajamul ;

Nayarisseri, Anuraj ;

Singh, Sanjeev K. .

CURRENT COMPUTER-AIDED DRUG DESIGN, 2021, 17 (03) :387-401

[2] Lenvatinib: A Review in Hepatocellular Carcinoma [J].

Al-Salama, Zaina T. ;

Syed, Yahiya Y. ;

Scott, Lesley J. .

DRUGS, 2019, 79 (06) :665-674

[3] Direct interactions among Ret, GDNF and GFRα1 molecules reveal new insights into the assembly of a functional three-protein complex [J].

Amoresano, A ;

Incoronato, M ;

Monti, G ;

Pucci, P ;

de Franciscis, V ;

Cerchia, L .

CELLULAR SIGNALLING, 2005, 17 (06) :717-727

[4] Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization [J].

Baker, Jessica A. ;

Sireci, Anthony N. ;

Marella, Narasimha ;

Cannon, Holly Kay ;

Marquart, Tyler J. ;

Holzer, Timothy R. ;

Reising, Leslie O'Neill ;

Cook, Joel D. ;

Wijayawardana, Sameera R. ;

Bodo, Juraj ;

Hsi, Eric D. ;

Schade, Andrew E. ;

Oakley, Gerard J. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2022, 146 (03) :351-359

[5] ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research [J].

Belli, C. ;

Penault-Llorca, F. ;

Ladanyi, M. ;

Normanno, N. ;

Scoazec, J-Y ;

Lacroix, L. ;

Reis-Filho, J. S. ;

Subbiah, V ;

Gainor, J. F. ;

Endris, V ;

Repetto, M. ;

Drilon, A. ;

Scarpa, A. ;

Andre, F. ;

Douillard, J-Y ;

Curigliano, G. .

ANNALS OF ONCOLOGY, 2021, 32 (03) :337-350

[6] High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden [J].

Benayed, Ryma ;

Offin, Michael ;

Mullaney, Kerry ;

Sukhadia, Purvil ;

Rios, Kelly ;

Desmeules, Patrice ;

Ptashkin, Ryan ;

Won, Helen ;

Chang, Jason ;

Halpenny, Darragh ;

Schram, Alison M. ;

Rudin, Charles M. ;

Hyman, David M. ;

Arcila, Maria E. ;

Berger, Michael F. ;

Zehir, Ahmet ;

Kris, Mark G. ;

Drilon, Alexander ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2019, 25 (15) :4712-4722

[7] RET Inhibitors in Non-Small-Cell Lung Cancer [J].

Cascetta, Priscilla ;

Sforza, Vincenzo ;

Manzo, Anna ;

Carillio, Guido ;

Palumbo, Giuliano ;

Esposito, Giovanna ;

Montanino, Agnese ;

Costanzo, Raffaele ;

Sandomenico, Claudia ;

De Cecio, Rossella ;

Piccirillo, Maria Carmela ;

La Manna, Carmine ;

Totaro, Giuseppe ;

Muto, Paolo ;

Picone, Carmine ;

Bianco, Roberto ;

Normanno, Nicola ;

Morabito, Alessandro .

CANCERS, 2021, 13 (17)

[8] EXON STRUCTURE AND FLANKING INTRONIC SEQUENCES OF THE HUMAN RET PROTOONCOGENE [J].

CECCHERINI, I ;

BOCCIARDI, R ;

LUO, Y ;

PASINI, B ;

HOFSTRA, R ;

TAKAHASHI, M ;

ROMEO, G .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 196 (03) :1288-1295

[9] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial [J].

Cella, David ;

Escudier, Bernard ;

Tannir, Nizar M. ;

Powles, Thomas ;

Donskov, Frede ;

Peltola, Katriina ;

Schmidinger, Manuela ;

Heng, Daniel Y. C. ;

Mainwaring, Paul N. ;

Hammers, Hans J. ;

Lee, Jae Lyun ;

Roth, Bruce J. ;

Marteau, Florence ;

Williams, Paul ;

Baer, John ;

Mangeshkar, Milan ;

Scheffold, Christian ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) :757-+

[10] Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells [J].

Chi, Wei ;

Zhang, Lianyong ;

Wang, Xue ;

Li, Jingjing ;

Li, Fei ;

Ma, Yuxia ;

Zhang, Qianyun .

INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) :709-717

← 1 2 3 4 5 6 7 8 9 10 →